SAT0483 Female sexual dysfunction in patients with systemic sclerosis

Background Systemic sclerosis (SSc) is a chronic autoimmune disease leading to various physical and psychological impairments including sexual dysfunction. Objectives To assess sexual functions/quality of life and pelvic floor function in female SSc patients compared to age-/sex-matched healthy controls (HC), and to analyse the potential impact of disease activity, fatigue, physical activity and depression. Methods In total, 41 women with SSc (mean age: 50.9, disease duration: 5.8 years, lcSSc/dcSSc: 18/23, mRSS: 13.6, ESSG activity index: 2.5), who fulfilled the ACR/EULAR 2013 criteria, and 41 healthy controls (mean age: 50.9) without rheumatic diseases filled in 12 well-established and validated questionnaires assessing sexual function/quality of life, pelvic floor function, fatigue, physical activity and depression. Full names of questionnaires are listed in the table 1. Data are presented as mean ±SEM. Results Compared to HC, patients with SSc had significantly higher prevalence and greater severity of sexual dysfunction (FSFI, BISF-W: in all subscales as well as total scores), dysfunction of pelvic floor (PISQ-12, PFIQ7), and worse sexual quality of life (SQol-F) (table 1). Worse scores in SSc patients were associated with higher disease activity [ESSG activity index: SQol-F (r=−0.364,p=0.0443), PFIQ7-gynaecological subscale (r=0.492,p=0.0036)], greater fatigue [all three questionnaires FSS/FIS/MAF correlated negatively with FSFI, BISF-W], more severe depression [BDI-II: FSFI (r=−0.553,p=0.0002), BISF-W (r=−0.514,p=0.0007), PFIQ7 (r=0.495,p=0,0010)], deteriorated quality of life [SHAQ: FSFI (r=−0.536,p=0.0003), BISF-W (r=−0.563,p=0.0001), SQol-F (r=−0.338,p=0.0382), PISQ-12 (r=0.563,p=0.0051), PFIQ7 (r=0.380,p=0.0142)], and worse ability to perform physical activities [HAP: FSFI (r=0.407,p=0.0082), BISF-W (r=0.409,p=0.0078)]. Questionnaire: score range Systemic sclerosis (n=41) Healthy controls (n=41) p-value FSFI: Female Sexual Function Index: 2(worst)−36(best) 15.2±1.7 25.0±1.7 p<0.0001 BISF-W: Brief Index of Sexual Function for Women: −16(worst)−75(best) 17.5±2.8 29.7±2.8 p=0.0027 PISQ–12: Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form: 0(best)−48(worst) 13.9±0.9 8.5±0.7 p<0.0001 PFIQ7: Pelvic Floor Distress Inventory Questionnaire – short form 7:0(best)−300(worst) 26.4±5.9 7.1±2.2 p=0.0092 SQoL-F: Sexual Quality of Life Questionnaire – Female: 0(worst)−100(best) 56.7±3.9 78.8±3.3 p<0.0001 FSS: Fatigue Severity Scale: 9(best)−63(worst) 40.7±2.2 6.9±1.0 p<0.0001 FIS: Fatigue Impact Scale: 0(best)−160(worst) 59.2±4.9 28.8±4.3 p<0.0001 MAF: Multidimensional Assessment of Fatigue Scale: 1(best)−50(worst) 26.0±1.6 13.6±1.3 p<0.0001 BDI-II: Beck’s Depression Inventory II: 0(best)−63(worst) 14.2±1.3 4.8±0.8 p<0.0001 HAP: Human Activity Profile–adjusted activity score: 0(worst)−94(best) 49.4±3.7 81.1±1.5 p<0.0001 HAQ: Health Assessment Questionnaire: 0(best)−3(worst) 0.9±0.1 0.1±0.0 p<0.0001 Conclusions Women with SSc reported significantly impaired sexual function, sexual quality of life and pelvic floor function than age-matched healthy controls. Worse scores in SSc were associated with disease activity, physical activity, fatigue, depression and quality of life. Acknowledgements Supported by AZV-16- 33574A and MHCR 023728. Disclosure of Interest None declared